Together, these findings support that activation of the FGFR1 signaling mainly upregulates FOXQ1 expression and breast cancer cell proliferation through activating ERK2, but not ERK1, in the FGFR1-MEK-ERK2 signaling pathway. This evidence concerns the gene MAPK3 and breast carcinoma.